Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma.
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
D'Ambrosio, Lorenzo;Pignochino, Ymera;Miano, Sara;Tolomeo, Francesco;Chiabotto, Giulia;Sangiolo, Dario;Bartolini, Alice;Bardelli, Alberto;Aglietta, Massimo
Last
2018-01-01
Abstract
Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Lancet Oncology 2018f.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
644.63 kB
Formato
Adobe PDF
|
644.63 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Onco-Aglietta.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
642.28 kB
Formato
Adobe PDF
|
642.28 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
